Incyte pays $53M upfront for Calithera I-O drug, setting stage for anti-PD-1 combo trials in solid tumors

Money
The deal gives Incyte a phase 1 asset that is being trialled in combination with Bristol-Myers' Opdivo

Incyte has paid $53 million upfront for Calithera Biosciences’ small molecule arginase inhibitor CB-1158. The deal sees Incyte sign up to codevelop an asset it sees complementing PD-1 drugs by reversing an immunosuppressive block that dampens the activity of immuno-oncology therapies.

Wilmington, DE-based Incyte is paying $45 million upfront and making an $8 million investment in Calithera to enter into the global collaboration and license agreement. The pact puts Incyte on the hook for 70% of the global development budget for CB-1158, as well as milestone payments that could total upward of $430 million. Incyte and Calithera have agreed a 60-40 split on U.S. profits, although the latter can forego these earnings in favor of more milestones and freedom from its commitment to the R&D budget.

In exchange for the outlay, Incyte is securing the rights to a therapy with the potential to boost the effectiveness of drugs in its immuno-oncology pipeline.

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

“Arginase-expressing tumor-infiltrating myeloid cells have been shown to play an important role in orchestrating the immune suppressive microenvironment in cancer; but, to date, therapeutic targeting of the arginase enzyme has remained elusive. The addition of this first-in-class, small molecule arginase inhibitor, CB-1158, to our portfolio expands our innovative immuno-oncology pipeline,” Incyte CSO Reid Huber said in a statement.

If CB-1158 works as hoped, it will hinder tumor growth by targeting arginase, an enzyme linked to the depletion of arginine in the tumor microenvironment and subsequent stunting of cytotoxic T cell and natural killer cell activity.

Calithera thinks this mechanism of action makes CB-1158 a natural bedfellow of anti-PD-1 drugs. The phase 1 trial Calithera started last year is looking at CB-1158 as a monotherapy and alongside Bristol-Myers Squibb’s Opdivo in patients with a handful of different types of solid tumor. Calithera sees CB-1158 working in any cancer that features arginase-secreting cells.

When the deal closes later this quarter, CB-1158 will join four other assets—including a PD-1 drug—in Incyte’s cancer immunotherapy pipeline.

Shares in Calithera rose more than 25% in premarket trading·

Suggested Articles

Novocure’s tumor-treating electric field system scored an FDA nod in mesothelioma, making it the first new treatment in more than 15 years.

FLX Bio is renaming itself RAPT Therapeutics to reflect its expansion into allergy and inflammatory diseases.

The preclinical-stage biotech wants the cash to take an antisense oligonucleotide treatment for Dravet syndrome through to phase 3.